FOLD
AMICUS THERAPEUTICS, INC.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Apr 27. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 46 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate $0.093 → −$0.082 over 90 days. 0 up, 1 down in 30 days.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| NORGES BANK | EXIT | $0.00 |
| STATE STREET CORP | EXIT | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| JPMORGAN CHASE & CO | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jan 2026| Date | Firm | Rating |
|---|---|---|
| Jan 22, 2026 | Jefferies DOWNGRADE | Hold |
| Dec 29, 2025 | Leerink Partners DOWNGRADE | Market Perform |
| Dec 22, 2025 | Citigroup DOWNGRADE | Neutral |
| Dec 19, 2025 | Needham DOWNGRADE | Hold |
| Dec 19, 2025 | Cantor Fitzgerald DOWNGRADE | Neutral |
| Dec 17, 2025 | Citigroup INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Clark David Michael Chief People Officer Apr 27, 2026 | TO ISSUER | 83,221 sh |
Rosenberg Ellen Chief Legal Officer Apr 27, 2026 | TO ISSUER | 108,980 sh |
Clark David Michael Chief People Officer Apr 27, 2026 | TO ISSUER | 108,266 sh |
Clark David Michael Chief People Officer Apr 27, 2026 | TO ISSUER | 91,439 sh |
Rosenberg Ellen Chief Legal Officer Apr 27, 2026 | TO ISSUER | 203,825 sh |
Harford Simon N.R. Chief Financial Officer Apr 27, 2026 | TO ISSUER | 99,073 sh |
Harford Simon N.R. Chief Financial Officer Apr 27, 2026 | TO ISSUER | 150,517 sh |
Campbell Bradley L President and CEO Apr 27, 2026 | TO ISSUER | $14.6M |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current FY | $0.07 | $0.07–$0.07 | -88.8% | $752.4M |
| Next FY | $0.82 | $0.47–$0.97 | -10.8% | $888.5M |
| Next Q | $0.02 | $0.02–$0.02 | -89.6% | $180.9M |
| Current Q | -$0.08 | -$0.08–-$0.08 | -188.0% | $159.6M |
Washington
SecBot reports
3 filings · 0 bullish · 0 bearish · 3 neutral- NEUTRAL 15-12GMay 7, 2026
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by…
The deregistration is a procedural step post-merger. FOLD shares will cease to be publicly traded. No further trading action is expected.
- NEUTRAL 8-KApr 27, 2026
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of…
The stock will cease trading following delisting, and FOLD shareholders have been paid out in full. No further corporate actions are expected as Amicus operates as a private subsidiary of BioMarin…
- NEUTRAL 8-KApr 23, 2026
Amicus Therapeutics announced that the French Ministry of Economics and Finance has granted…
Traders should monitor for the official closing announcement on or around April 27, 2026, which will confirm the delisting of FOLD shares and completion of the acquisition. Arbitrage opportunities…
All FOLD filing & press-release reports (3)
- 15-12G reportMay 7, 2026
- 8-K reportApr 27, 2026
- 8-K reportApr 23, 2026